IP Library Granted Patent US 10,435,710
Granted Patent B2
US 10,435,710 · App. 15/590,209 · Granted Oct 8, 2019

Engineering a heterogeneous tissue from pluripotent stem cells

Inventors: Patrick Guye (Cambridge, MA); Ron Weiss (Newton, MA); Mohammad Reza Ebrahimkhani (Somerville, MA)
Assignee: Massachusetts Institute of Technology
C12N15/85C07K14/4705C12N5/0696G01N33/5014C12N2510/00C12N2799/027
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,435,710
App. No.
15/590,209
Granted
Oct 8, 2019
Kind
B2
Abstract

Aspects of the present disclosure are directed to methods and compositions for the production of heterogeneous tissue from human induced pluripotent stem (hiPS) cells.

Claims (13)

1. A cultured heterogeneous tissue containing a mixture of mesodermal cell types, endodermal cell types and ectodermal cell types, wherein the heterogeneous tissue is derived from human induced pluripotent stem cells that comprise a nucleic acid comprising an inducible promoter operably linked to a nucleic acid encoding GATA6 protein.

2. The cultured heterogeneous tissue of claim 1 comprising cells that express biomarkers indicative of at least two cell types selected from: cholangiocyte-like cells (ChLCs), endothelial-like cells (EnLCs), endothelial progenitors (EPs), erythrocyte-like cells (ErLCs), hematopoietic progenitor-like cells (HmLCs), hemogenic endothelium (HEs), hepatic endoderm (HpEn), hepatoblast-like cells (HpLCs), mesenchymal progenitors (MPs), mesenchyme-like cells (MsLCs), neuroectoderm (NEc), neural fold-like cells (NfLCs), neural plate-like cells (NpLCs) and stellate-like cells (StLCs).

3. The cultured heterogeneous tissue of claim 2 comprising HpLCs, ChLCs, EnLCs, HmLCs, and StLCs that co-develop in the heterogeneous tissue.

4. The cultured heterogeneous tissue of claim 3 , wherein the HpLCs express at least one biomarker selected from: CD133, AAT, CEBPA, FOXA2, AFP, LGR5 and CK19.

5. The cultured heterogeneous tissue of claim 4 , wherein the HpLCs express CD133, AAT, CEBPA, FOXA2, AFP, LGR5 and CK19.

6. The cultured heterogeneous tissue of claim 3 , wherein the ChLCs express CK7 and/or AQP1.

7. The cultured heterogeneous tissue of claim 3 , wherein the EnLCs express CD31.

8. The cultured heterogeneous tissue of claim 3 , wherein the HmLCs express CD45.

9. The cultured heterogeneous tissue of claim 3 , wherein the StLCs express DES.

10. A cultured heterogeneous tissue comprising cells that form an endothelial-like tube embedded in hepatoblast-like tissue, wherein the heterogeneous tissue is derived from human induced pluripotent stem cells that comprise a nucleic acid comprising an inducible promoter operably linked to a nucleic acid encoding GATA6 protein.

11. The cultured heterogeneous tissue of claim 10 , wherein cells of the endothelial-like tube express at least one biomarker selected from: CD34, CD146, TAL1 and FLK1.

12. The cultured heterogeneous tissue of claim 11 , wherein cells of the endothelial-like tube express CD34, CD146, TAL1 and FLK1.

13. The cultured heterogeneous tissue of claim 10 , wherein cells of the endothelial-like tube do not express CEBPA and/or HNF4A.

Assignments (2)
CONFIRMATORY LICENSE Recorded Jun 10, 2019
From: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 049415/0217 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 10, 2019
From: GUYE, PATRICK; WEISS, RON; EBRAHIMKHARI, MOHAMMAD REZA
To: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Reel/Frame 049139/0317 →
Continuity (3)
Continuation 14218426 · Mar 18, 2014
Provisional Application 61802931 · Mar 18, 2013
Related Publication 20170306351A1 · Oct 26, 2017
Cited By (1)
US 12,692,479